Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-20093 in advanced solid tumors and HNSCC
NCT06007729Phase 2Recruiting
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Dec 2023
- Primary completion
- Dec 2025
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of risvutatug rezetecan in head and neck squamous cell carcinoma (HNSCC), solid tumor, sponsored by Hansoh Pharmaceutical Group. Started Dec 2023; status: recruiting.
02
Drugs
risvutatug rezetecan
03
Conditions
head and neck squamous cell carcinoma (HNSCC)solid tumor
Beyond the preview
Go deeper on NCT06007729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06007729.